Dr Li is a Assistant Professor jointly by the Department of Medicine and Department of Pharmacology and Pharmacy, University of Hong Kong (HKU). Before joining HKU, she obtained Master of Medicine at Peking Union Medical College, Tsinghua University and PhD in Public Health at the Chinese University of Hong Kong. Dr Li’s primary research interest is health technology assessment (HTA), health economics and real-world outcome (HEOR) research using decision analytic models and electronic health records (healthcare big data). She is expertise on budget impact, and cost-effectiveness analyses for new drugs market access, population-based disease burden estimation, big-data based health policy evaluation and patient-reported outcome research. She has been published actively in the field of public health science and health policy, covering the therapeutic areas of infectious diseases and vaccinology, cardiovascular diseases, diabetes mellitus, autoimmune diseases and rare diseases.She also serves as peer-reviewers for Value in Health, PlosOne and ISPOR conferences. Dr Li has led and contributed to many pharmacoeconomics projects, which had dynamic interactions with the international academic collaborators, local government, industry, community, patients’ group and other key opinion leaders. Her recent research focuses on the real-world evidence of rare disease and orphan drugs and the development of performance-based risk-sharing model for innovative and curative therapies.